Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease

Next Previous
X
Search
Trial Profile

A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tafenoquine (Primary)
  • Indications COVID 2019 infections; Severe acute respiratory syndrome
  • Focus Therapeutic Use
  • Acronyms TQ 2020_06
  • Sponsors 60 Degrees Pharmaceuticals

    • Most Recent Events

    • 21 Jun 2022 According to a 60 Degrees Pharmaceuticals media release, for strategic reasons related to a rapidly changing pandemic and competitive environment, 60P elected to terminate the study early and unblind the data from n=86 patients. Early unblinding made the study underpowered to achieve its primary statistical endpoint.
    • 21 Jun 2022 Status changed from active, no longer recruiting to discontinued, according to a 60 Degrees Pharmaceuticals media release.
    • 21 Jun 2022 According to a 60 Degrees Pharmaceuticals media release, the preliminary results of this study have been published in the peer-reviewed journal, New Microbes and New Infections.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top